Q-omics provides the consensus-scored CDRT15P14 profile across patient tissues and cancer cell-line models. CDRT15P14 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, CDRT15P14 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, CDRT15P14 RNA expression shows 5,383 significant pathway-activity associations, with the highest sampling consensus in HNSC. Together, these results highlight STAD, KICH, and HNSC as cancer lineages where CDRT15P14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDRT15P14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDRT15P14 survival associations across molecular data types. CDRT15P14 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDRT15P14 RNA expression–survival associations across cancer types. High CDRT15P14 expression shows unfavorable associations in STAD, BRCA, KIRP, BLCA and DLBC, but favorable associations in ACC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for CDRT15P14 RNA expression.
This table summarizes CDRT15P14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for CDRT15P14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDRT15P14 shows lower tumor expression in KICH and BRCA and higher tumor expression in LIHC, LUSC, LUAD and CHOL. The KICH box plot shows higher CDRT15P14 RNA expression in normal versus tumor tissue (log2 FC = −0.113, t-test p = .020).
This table shows molecular features associated with CDRT15P14 in patient tissues and cancer cell lines. In patient samples, CDRT15P14 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
